» Articles » PMID: 29977644

Primary Sclerosing Cholangitis: A Review and Update

Overview
Journal Liver Res
Date 2018 Jul 7
PMID 29977644
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease of uncertain etiology characterized biochemically by cholestasis and histologically and cholangiographically by fibro-obliterative inflammation of the bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and/or hepatobiliary cancer, though the disease course can be highly variable. Despite clinical trials of numerous pharmacotherapies over several decades, safe and effective medical therapy remains to be established. Liver transplantation is an option for select patients with severe complications of PSC, and its outcomes are generally favorable. Periodic surveillance testing for pre- as well as post-transplant patients is a cornerstone of preventive care and health maintenance. Here we provide an overview of PSC including its epidemiology, etiopathogenesis, clinical features, associated disorders, surveillance, and emerging potential therapies.

Citing Articles

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.

Fiorucci S, Urbani G, Di Giorgio C, Biagioli M, Distrutti E Cells. 2024; 13(19.

PMID: 39404413 PMC: 11475195. DOI: 10.3390/cells13191650.


Primary sclerosing cholangitis: Is qualitative and quantitative 3 T MR imaging useful for the evaluation of disease severity?.

Boraschi P, Mazzantini V, Donati F, Coco B, Vianello B, Pinna A Eur J Radiol Open. 2024; 13:100595.

PMID: 39206437 PMC: 11357777. DOI: 10.1016/j.ejro.2024.100595.


A framework for exclusion of alternative diagnoses in sarcoidosis.

Harper L, Farver C, Yadav R, Culver D J Autoimmun. 2024; 149:103288.

PMID: 39084998 PMC: 11791745. DOI: 10.1016/j.jaut.2024.103288.


Caregiver-reported symptom burden and preferences for therapeutic goals in pediatric primary sclerosing cholangitis.

Shifman H, Hatchett J, Pai R, Safer R, Gomel R, Vyas M J Pediatr Gastroenterol Nutr. 2024; 79(4):835-840.

PMID: 38899591 PMC: 11444895. DOI: 10.1002/jpn3.12287.


Increasing Prevalence and High Survival Rate of Liver Transplanted Patients with NASH and PSC Cirrhosis.

Khajehahmadi Z, Nikeghbalian S, Roshanaei G, Mohagheghi S Arch Iran Med. 2024; 27(1):23-29.

PMID: 38431957 PMC: 10915929. DOI: 10.34172/aim.2024.04.


References
1.
Olsson R, Bjornsson E, Backman L, Friman S, Hockerstedt K, Kaijser B . Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol. 1998; 28(3):426-32. DOI: 10.1016/s0168-8278(98)80316-4. View

2.
Tabibian J, Lindor K . Challenges of Cholangiocarcinoma Detection in Patients with Primary Sclerosing Cholangitis. J Anal Oncol. 2020; 1(1):50-55. PMC: 6939639. DOI: 10.6000/1927-7229.2012.01.01.7. View

3.
Goss J, Shackleton C, Farmer D, Arnaout W, Seu P, Markowitz J . Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg. 1997; 225(5):472-81; discussion 481-3. PMC: 1190779. DOI: 10.1097/00000658-199705000-00004. View

4.
Duboc H, Rajca S, Rainteau D, Benarous D, Maubert M, Quervain E . Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut. 2012; 62(4):531-9. DOI: 10.1136/gutjnl-2012-302578. View

5.
Wilschanski M, Chait P, Wade J, Davis L, Corey M, St Louis P . Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysis. Hepatology. 1995; 22(5):1415-22. View